Revvity Inc. Announces Strategic Collaboration with Profluent to Enhance Gene Editing Platform

Reuters

2025/09/22

Revvity Inc. Announces Strategic Collaboration with Profluent to Enhance Gene Editing Platform

Revvity Inc. has announced a strategic collaboration with Profluent to enhance its gene editing capabilities. The partnership combines Profluent's AI-engineered enzymes with Revvity's Pin-point base editing platform, providing customers with access to a comprehensive base editing toolkit. This collaboration aims to facilitate the development of novel gene editing therapies by offering a customizable and therapeutically relevant system. By integrating Profluent's proteins, Revvity's Pin-point platform seeks to expand the potential to address a wider range of disease-related mutations. The collaboration reflects both companies' commitment to advancing base editing technologies and accelerating the creation of life-changing therapies. Revvity plans to present the new AI-enhanced adenine deaminase Pin-point system at the ESGCT 2025 Annual Congress.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Revvity Inc. published the original content used to generate this news brief via Business Wire (Ref. ID: 20250922513581) on September 22, 2025, and is solely responsible for the information contained therein.

應版權方要求，你需要登入查看該內容

登入 / 註冊

免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。

熱議股票

1
2
3
4
5
6
7
8
9
10

{"basename":"/hant","ssrTDKData":{"titleTemplate":"%s - 老虎證券","title":"老虎证券全球投资理财平台| 一站式投资美股新股港股A股","description":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","keywords":"老虎證券,老虎證券開戶,老虎券商,老虎證券官網,老虎證券app,tigertrade老虎證券,股票,炒股,新加坡股票交易平臺,投資,投資理財","social":{"ogDescription":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/hant/news/2569784899"},"companyName":"老虎證券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2569784899\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/2569784899?lang=zh_TW&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-09-22 20:01","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2569784899","market":"fut","top_or_hot":-1,"title":"Revvity Inc. Announces Strategic Collaboration with Profluent to Enhance Gene Editing Platform","media":"Reuters","content":"<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      Revvity Inc. Announces Strategic Collaboration with Profluent to Enhance Gene Editing Platform\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n        Revvity Inc. has announced a strategic collaboration with Profluent to enhance its gene editing capabilities. The partnership combines Profluent's AI-engineered enzymes with Revvity's Pin-point base editing platform, providing customers with access to a comprehensive base editing toolkit. This collaboration aims to facilitate the development of novel gene editing therapies by offering a customizable and therapeutically relevant system. By integrating Profluent's proteins, Revvity's Pin-point platform seeks to expand the potential to address a wider range of disease-related mutations. The collaboration reflects both companies' commitment to advancing base editing technologies and accelerating the creation of life-changing therapies. Revvity plans to present the new AI-enhanced adenine deaminase Pin-point system at the ESGCT 2025 Annual Congress.\n      </p>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<em>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Revvity Inc. published the original content used to generate this news brief via Business Wire (Ref. ID: 20250922513581) on September 22, 2025, and is solely responsible for the information contained therein.</span></em>\n</div></body></html>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Revvity Inc. Announces Strategic Collaboration with Profluent to Enhance Gene Editing Platform</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 12.5px; color: #7E829C; margin: 0;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nRevvity Inc. Announces Strategic Collaboration with Profluent to Enhance Gene Editing Platform\n</h2>\n<h4 class=\"meta\">\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1032215980\">\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Reuters </p>\n<p class=\"h-time smaller\">2025-09-22 20:01</p>\n</div>\n</a>\n</h4>\n</header>\n<article>\n<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      Revvity Inc. Announces Strategic Collaboration with Profluent to Enhance Gene Editing Platform\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n        Revvity Inc. has announced a strategic collaboration with Profluent to enhance its gene editing capabilities. The partnership combines Profluent's AI-engineered enzymes with Revvity's Pin-point base editing platform, providing customers with access to a comprehensive base editing toolkit. This collaboration aims to facilitate the development of novel gene editing therapies by offering a customizable and therapeutically relevant system. By integrating Profluent's proteins, Revvity's Pin-point platform seeks to expand the potential to address a wider range of disease-related mutations. The collaboration reflects both companies' commitment to advancing base editing technologies and accelerating the creation of life-changing therapies. Revvity plans to present the new AI-enhanced adenine deaminase Pin-point system at the ESGCT 2025 Annual Congress.\n      </p>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<em>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Revvity Inc. published the original content used to generate this news brief via Business Wire (Ref. ID: 20250922513581) on September 22, 2025, and is solely responsible for the information contained therein.</span></em>\n</div></body></html>\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK4121","symbol_name":"生命科學工具和服務","start_time":0,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250922:nNDL2wB4Hb:1","article_id":"2569784899","we_media_id":"1032215980","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2569784899","pubTimestamp":1758542476,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Reuters","introduction":"Reuters.com brings you the latest news from around the world, covering breaking news in markets, business, politics, entertainment and technology","home_visible":1,"id":"1032215980","head_image":"https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48"},"summary":"Revvity Inc. has announced a strategic collaboration with Profluent to enhance its gene editing capabilities. The partnership combines Profluent's AI-engineered enzymes with Revvity's Pin-point base editing platform, providing customers with access to a comprehensive base editing toolkit. This collaboration aims to facilitate the development of novel gene editing therapies by offering a customizable and therapeutically relevant system. By integrating Profluent's proteins, Revvity's Pin-point platform seeks to expand the potential to address a wider range of disease-related mutations. The collaboration reflects both companies' commitment to advancing base editing technologies and accelerating the creation of life-changing therapies. Revvity plans to present the new AI-enhanced adenine deaminase Pin-point system at the ESGCT 2025 Annual Congress.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"BK4121":"生命科学工具和服务","RVTY":"REVVITY INC","BK4588":"碎股","BK4585":"ETF&股票定投概念"},"translate_title":"Revvity Inc.宣布与Profluent开展战略合作，增强基因编辑平台","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"RVTY":0.9},"content_text":"Revvity Inc. Announces Strategic Collaboration with Profluent to Enhance Gene Editing Platform\n    \n\n        Revvity Inc. has announced a strategic collaboration with Profluent to enhance its gene editing capabilities. The partnership combines Profluent's AI-engineered enzymes with Revvity's Pin-point base editing platform, providing customers with access to a comprehensive base editing toolkit. This collaboration aims to facilitate the development of novel gene editing therapies by offering a customizable and therapeutically relevant system. By integrating Profluent's proteins, Revvity's Pin-point platform seeks to expand the potential to address a wider range of disease-related mutations. The collaboration reflects both companies' commitment to advancing base editing technologies and accelerating the creation of life-changing therapies. Revvity plans to present the new AI-enhanced adenine deaminase Pin-point system at the ESGCT 2025 Annual Congress.\n      \n\nDisclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Revvity Inc. published the original content used to generate this news brief via Business Wire (Ref. ID: 20250922513581) on September 22, 2025, and is solely responsible for the information contained therein.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"corporation","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":true,"code":"91000000","status":"200"}}}